News and views

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment...

COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights

Compass Pathways announces CFO transition

Compass Pathways appoints Daphne Karydas to its Board of Directors

Compass Pathways announces publication of first study evaluating potential of AI model to predict ou...

Compass Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthca...

Compass Pathways Announces Second Quarter 2023 Financial Results and Business Highlights

First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicin...

Compass Pathways announces publication of positive data from treatment-resistant depression phase 2 ...

Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psiloc...

American Medical Association Releases Language of First New Current Procedural Terminology Code for ...

Compass Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital